Abstract
Alzheimer’s disease (AD) and diabetes are among the most common diseases associated with ageing. The pathology of AD is strongly associated with accumulated misfolding proteins that results in neuronal dysfunction within the brain. Diabetes, on the contrary, is characterised by altered insulin signaling that results in reduced glucose uptake, metabolic suppression of energy consuming cells and conversion of glucose to fat in the liver. Despite distinguishing features, these diseases share common elements and may in fact be viewed as fundamentally similar disorders that differ in magnitude of specific traits, primarily affected tissues and time of onset. In this review, we outline the fundamental basis of each of the two diseases and highlight similarities in their pathophysiology. Further ahead we will discuss these features in relation to the development of drugs to treat these two diseases, particularly AD, for which the development of therapeutic chemicals has proven to be particularly difficult. We conclude with comments on efforts to develop a simple organism, Caenorhabditis elegans, as a genetic model to be used to study the systems biology of diabetes and AD.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Citron M (2004) Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci 5(9):677–685. doi:10.1038/nrn1495
Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, Takeuchi D, Kurinami H, Shinohara M, Rakugi H, Morishita R (2010) Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci U S A 107(15):7036–7041. doi:10.1073/pnas.1000645107
Iqbal K, Grundke-Iqbal I (2006) Discoveries of tau, abnormally hyperphosphorylated tau and others of neurofibrillary degeneration: a personal historical perspective. J Alzheimers Dis 9(3 Suppl):219–242
Lin EH, Rutter CM, Katon W, Heckbert SR, Ciechanowski P, Oliver MM, Ludman EJ, Young BA, Williams LH, McCulloch DK, Von Korff M (2010) Depression and advanced complications of diabetes: a prospective cohort study. Diabetes Care 33(2):264–269. doi:10.2337/dc09-1068
Jakicic JM, Jaramillo SA, Balasubramanyam A, Bancroft B, Curtis JM, Mathews A, Pereira M, Regensteiner JG, Ribisl PM, Look ASG (2009) Effect of a lifestyle intervention on change in cardiorespiratory fitness in adults with type 2 diabetes: results from the Look AHEAD Study. Int J Obes 33(3):305–316. doi:10.1038/ijo.2008.280
Virkamaki A, Ueki K, Kahn CR (1999) Protein–protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Investig 103(7):931–943. doi:10.1172/JCI6609
Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monte SM (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease—is this type 3 diabetes? J Alzheimers Dis 7(1):63–80
Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM (2005) Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis 8(3):247–268
Umegaki H (2012) Neurodegeneration in diabetes mellitus. Adv Exp Med Biol 724:258–265. doi:10.1007/978-1-4614-0653-219
Correia SC, Santos RX, Perry G, Zhu X, Moreira PI, Smith MA (2011) Insulin-resistant brain state: the culprit in sporadic Alzheimer's disease? Ageing Res Rev 10(2):264–273. doi:10.1016/j.arr.2011.01.001
Ristow M (2004) Neurodegenerative disorders associated with diabetes mellitus. J Mol Med 82(8):510–529. doi:10.1007/s00109-004-0552-1
Roche E, Reig JA, Campos A, Paredes B, Isaac JR, Lim S, Calne RY, Soria B (2005) Insulin-secreting cells derived from stem cells: clinical perspectives, hypes and hopes. Transpl Immunol 15(2):113–129. doi:10.1016/j.trim.2005.09.008
Watson GS, Craft S (2004) Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease. Eur J Pharmacol 490(1–3):97–113. doi:10.1016/j.ejphar.2004.02.048
Sun MK, Alkon DL (2006) Links between Alzheimer's disease and diabetes. Drugs today 42(7):481–489. doi:10.1358/dot.2006.42.7.973588
Hoyer S (2004) Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol 490(1–3):115–125. doi:10.1016/j.ejphar.2004.02.049
Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM (1999) Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 53(9):1937–1942
Pasquier F, Boulogne A, Leys D, Fontaine P (2006) Diabetes mellitus and dementia. Diabetes Metabol 32(5 Pt 1):403–414
Sjogren M, Mielke M, Gustafson D, Zandi P, Skoog I (2006) Cholesterol and Alzheimer's disease—is there a relation? Mech Ageing Dev 127(2):138–147. doi:10.1016/j.mad.2005.09.020
Leoni V, Solomon A, Kivipelto M (2010) Links between ApoE, brain cholesterol metabolism, tau and amyloid beta-peptide in patients with cognitive impairment. Biochem Soc Trans 38(4):1021–1025. doi:10.1042/BST0381021
Deng Y, Li B, Liu Y, Iqbal K, Grundke-Iqbal I, Gong CX (2009) Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: Implication for Alzheimer's disease. Am J Pathol 175(5):2089–2098. doi:10.2353/ajpath.2009.090157
Hoyer S, Nitsch R (1989) Cerebral excess release of neurotransmitter amino acids subsequent to reduced cerebral glucose metabolism in early-onset dementia of Alzheimer type. J Neural Transm 75(3):227–232
Li L (2007) Is Glucagon-like peptide-1, an agent treating diabetes, a new hope for Alzheimer's disease? Neurosci Bull 23(1):58–65
Perry T, Greig NH (2002) The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease. J Alzheimers Dis 4(6):487–496
Li L, Holscher C (2007) Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res Rev 56(2):384–402. doi:10.1016/j.brainresrev.2007.09.001
Chouliaras L, Rutten BP, Kenis G, Peerbooms O, Visser PJ, Verhey F, van Os J, Steinbusch HW, van den Hove DL (2010) Epigenetic regulation in the pathophysiology of Alzheimer's disease. Prog Neurobiol 90(4):498–510. doi:10.1016/j.pneurobio.2010.01.002
Ling C, Groop L (2009) Epigenetics: a molecular link between environmental factors and type 2 diabetes. Diabetes 58(12):2718–2725. doi:10.2337/db09-1003
Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA (2003) Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 60(8):1119–1122. doi:10.1001/archneur.60.8.1119
Lopez OL (2011) The growing burden of Alzheimer's disease. Am J Manage Care 17(Suppl 13):S339–S345
Selvin E, Coresh J, Brancati FL (2006) The burden and treatment of diabetes in elderly individuals in the U.S. Diabetes Care 29(11):2415–2419. doi:10.2337/dc06-1058
Colman RJ, Anderson RM, Johnson SC, Kastman EK, Kosmatka KJ, Beasley TM, Allison DB, Cruzen C, Simmons HA, Kemnitz JW, Weindruch R (2009) Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 325(5937):201–204. doi:10.1126/science.1173635
Ford D, Ions LJ, Alatawi F, Wakeling LA (2011) The potential role of epigenetic responses to diet in ageing. Proc Nutr Soc 70(3):374–384. doi:10.1017/S0029665111000851
Cruzen C, Colman RJ (2009) Effects of caloric restriction on cardiovascular aging in non-human primates and humans. Clin Geriatr Med 25(4):733–743. doi:10.1016/j.cger.2009.07.001
Gonzalez O, Tobia C, Ebersole J, Novak MJ (2012) Caloric restriction and chronic inflammatory diseases. Oral Dis 18(1):16–31. doi:10.1111/j.1601-0825.2011.01830.x
Mandal S, Hart N (2012) Respiratory complications of obesity. Clin Med 12(1):75–78
Reaven GM (2011) Insulin resistance: the link between obesity and cardiovascular disease. Med Clin North Am 95(5):875–892. doi:10.1016/j.mcna.2011.06.002
Anstey KJ, Cherbuin N, Budge M, Young J (2011) Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies. Obes Rev 12(5):e426–e437. doi:10.1111/j.1467-789X.2010.00825.x
Slomko H, Heo HJ, Einstein FH (2012) Minireview: epigenetics of obesity and diabetes in humans. Endocrinology 153(3):1025–1030. doi:10.1210/en.2011-1759
Wolf PA, Beiser A, Elias MF, Au R, Vasan RS, Seshadri S (2007) Relation of obesity to cognitive function: importance of central obesity and synergistic influence of concomitant hypertension. The Framingham Heart Study. Curr Alzheimer Res 4(2):111–116
Luchsinger JA (2008) Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease: an epidemiological perspective. Eur J Pharmacol 585(1):119–129. doi:10.1016/j.ejphar.2008.02.048
Cheng D, Noble J, Tang MX, Schupf N, Mayeux R, Luchsinger JA (2011) Type 2 diabetes and late-onset Alzheimer's disease. Dement Geriatr Cogn Disord 31(6):424–430. doi:10.1159/000324134
Iglseder B (2011) Diabetes mellitus and cognitive decline. Wien Med Wochenschr 161(21–22):524–530. doi:10.1007/s10354-011-0003-x
Llibre Jde J, Valhuerdi A, Calvo M, Garcia RM, Guerra M, Laucerique T, Lopez AM, Llibre JC, Noriega L, Sanchez IY, Porto R, Arencibia F, Marcheco B, Moreno C (2011) Dementia and other chronic diseases in older adults in Havana and Matanzas: the 10/66 study in Cuba. MEDICC rev 13(4):30–37
Tripathi M, Vibha D, Gupta P, Bhatia R, Srivastava MV, Vivekanandhan S, Bhushan Singh M, Prasad K, Dergalust S, Mendez MF (2012) Risk factors of dementia in North India: a case–control study. Aging Ment Health 16(2):228–235. doi:10.1080/13607863.2011.583632
Accardi G, Caruso C, Colonna-Romano G, Camarda C, Monastero R, Candore G (2012) Can Alzheimer disease be a form of type 3 diabetes? Rejuvenation Res 15(2):217–221. doi:10.1089/rej.2011.1289
de la Monte SM, Wands JR (2008) Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Tech 2(6):1101–1113
Soto C (2003) Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci 4(1):49–60. doi:10.1038/nrn1007
Reitz C (2012) Alzheimer's disease and the amyloid cascade hypothesis: a critical review. Int J Alzheimers Dis 2012:369808. doi:10.1155/2012/369808
Milojevic J, Melacini G (2011) Stoichiometry and affinity of the human serum albumin-Alzheimer's Abeta peptide interactions. Biophys J 100(1):183–192. doi:10.1016/j.bpj.2010.11.037
Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14(8):837–842. doi:10.1038/nm1782
DeToma AS, Salamekh S, Ramamoorthy A, Lim MH (2012) Misfolded proteins in Alzheimer's disease and type II diabetes. Chem Soc Rev 41(2):608–621. doi:10.1039/c1cs15112f
Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8(2):101–112. doi:10.1038/nrm2101
Correia SC, Santos RX, Carvalho C, Cardoso S, Candeias E, Santos MS, Oliveira CR, Moreira PI (2012) Insulin signaling, glucose metabolism and mitochondria: major players in Alzheimer's disease and diabetes interrelation. Brain Res 1441:64–78. doi:10.1016/j.brainres.2011.12.063
Luca S, Yau WM, Leapman R, Tycko R (2007) Peptide conformation and supramolecular organization in amylin fibrils: constraints from solid-state NMR. Biochemistry 46(47):13505–13522. doi:10.1021/bi701427q
Woods SC, Lutz TA, Geary N, Langhans W (2006) Pancreatic signals controlling food intake; insulin, glucagon and amylin. Philos Trans R Soc B Biol Sci 361(1471):1219–1235. doi:10.1098/rstb.2006.1858
Haataja L, Gurlo T, Huang CJ, Butler PC (2008) Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr Rev 29(3):303–316. doi:10.1210/er.2007-0037
Zraika S, Hull RL, Udayasankar J, Aston-Mourney K, Subramanian SL, Kisilevsky R, Szarek WA, Kahn SE (2009) Oxidative stress is induced by islet amyloid formation and time-dependently mediates amyloid-induced beta cell apoptosis. Diabetologia 52(4):626–635. doi:10.1007/s00125-008-1255-x
Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC (2004) Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53(2):474–481
Fu W, Ruangkittisakul A, MacTavish D, Shi JY, Ballanyi K, Jhamandas JH (2012) Amyloid beta (Abeta) peptide directly activates amylin-3 receptor subtype by triggering multiple intracellular signaling pathways. J Biol Chem 287(22):18820–18830. doi:10.1074/jbc.M111.331181
Scherzer-Attali R, Shaltiel-Karyo R, Adalist YH, Segal D, Gazit E (2012) Generic inhibition of amyloidogenic proteins by two naphthoquinone–tryptophan hybrid molecules. Proteins 80(8):1962–1973. doi:10.1002/prot.24080
Gupta R, Kapoor N, Raleigh DP, Sakmar TP (2012) Nucleobindin 1 caps human islet amyloid polypeptide protofibrils to prevent amyloid fibril formation. J Mol Biol 421(2–3):378–389. doi:10.1016/j.jmb.2012.04.017
Sesti G (2006) Pathophysiology of insulin resistance. Best Pract Res Clin Endocrinol Metab 20(4):665–679. doi:10.1016/j.beem.2006.09.007
Yang XL, Chan JC (2012) Diabetes, insulin and cancer risk. World J Diabetes 3(4):60–64. doi:10.4239/wjd.v3.i4.60
Banks WA (2004) The source of cerebral insulin. Eur J Pharmacol 490(1–3):5–12. doi:10.1016/j.ejphar.2004.02.040
Bosco D, Fava A, Plastino M, Montalcini T, Pujia A (2011) Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis. J Cell Mol Med 15(9):1807–1821. doi:10.1111/j.1582-4934.2011.01318.x
Wang Q, Jin T (2009) The role of insulin signaling in the development of beta-cell dysfunction and diabetes. Islets 1(2):95–101. doi:10.4161/isl.1.2.9263
Thorens B (2012) Sensing of glucose in the brain. Handb Exp Pharmacol 209:277–294. doi:10.1007/978-3-642-24716-3_12
Pansuria M, Xi H, Li L, Yang XF, Wang H (2012) Insulin resistance, metabolic stress, and atherosclerosis. Front Biosci 4:916–931
Collino M, Aragno M, Castiglia S, Tomasinelli C, Thiemermann C, Boccuzzi G, Fantozzi R (2009) Insulin reduces cerebral ischemia/reperfusion injury in the hippocampus of diabetic rats: a role for glycogen synthase kinase-3beta. Diabetes 58(1):235–242. doi:10.2337/db08-0691
Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, Arvanitakis Z, Schneider JA, Wolf BA, Bennett DA, Trojanowski JQ, Arnold SE (2012) Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Investig 122(4):1316–1338. doi:10.1172/JCI59903
Park SA (2011) A common pathogenic mechanism linking type-2 diabetes and Alzheimer's disease: evidence from animal models. J Clin Neurol 7(1):10–18. doi:10.3988/jcn.2011.7.1.10
Li ZG, Zhang W, Sima AA (2007) Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes 56(7):1817–1824. doi:10.2337/db07-0171
Shingo AS, Kanabayashi T, Murase T, Kito S (2012) Cognitive decline in STZ-3 V rats is largely due to dysfunctional insulin signalling through the dentate gyrus. Behav Brain Res 229(2):378–383. doi:10.1016/j.bbr.2012.01.034
Zemva J, Schubert M (2011) Central insulin and insulin-like growth factor-1 signaling: implications for diabetes associated dementia. Curr Diabetes Rev 7(5):356–366
Zhao WQ, De Felice FG, Fernandez S, Chen H, Lambert MP, Quon MJ, Krafft GA, Klein WL (2008) Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 22(1):246–260. doi:10.1096/fj.06-7703com
Gasparini L, Gouras GK, Wang R, Gross RS, Beal MF, Greengard P, Xu H (2001) Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci 21(8):2561–2570
Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, Frosch MP, Selkoe DJ (2003) Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40(6):1087–1093
Leal MC, Fernandez Gamba A, Morelli L, Castano EM (2009) Cerebral proteolysis of amiloid-b peptide: relevance of insulin-degrading enzyme in Alzheimer's disease. Medicina 69(4):466–472
Parihar MS, Brewer GJ (2010) Amyloid-beta as a modulator of synaptic plasticity. J Alzheimers Dis 22(3):741–763. doi:10.3233/JAD-2010-101020
Brezar V, Carel JC, Boitard C, Mallone R (2011) Beyond the hormone: insulin as an autoimmune target in type 1 diabetes. Endocr Rev 32(5):623–669. doi:10.1210/er.2011-0010
Al-Qatati A, Winter PW, Wolf-Ringwall AL, Chatterjee PB, Van Orden AK, Crans DC, Roess DA, Barisas BG (2012) Insulin receptors and downstream substrates associate with membrane microdomains after treatment with insulin or chromium(III) picolinate. Cell Biochem Biophys 62(3):441–450. doi:10.1007/s12013-011-9326-x
Denley A, Carroll JM, Brierley GV, Cosgrove L, Wallace J, Forbes B, Roberts CT Jr (2007) Differential activation of insulin receptor substrates 1 and 2 by insulin-like growth factor-activated insulin receptors. Mol Cell Biol 27(10):3569–3577. doi:10.1128/MCB.01447-06
Hulmi JJ, Silvennoinen M, Lehti M, Kivela R, Kainulainen H (2012) Altered REDD1, myostatin, and Akt/mTOR/FoxO/MAPK signaling in streptozotocin-induced diabetic muscle atrophy. Am J Physiol Endocrinol Metab 302(3):E307–E315. doi:10.1152/ajpendo.00398.2011
Machado-Neto JA, Favaro P, Lazarini M, Costa FF, Olalla Saad ST, Traina F (2011) Knockdown of insulin receptor substrate 1 reduces proliferation and downregulates Akt/mTOR and MAPK pathways in K562 cells. Biochim Biophys Acta 1813(8):1404–1411. doi:10.1016/j.bbamcr.2011.04.002
Duarte AI, Moreira PI, Oliveira CR (2012) Insulin in central nervous system: more than just a peripheral hormone. J Aging Res 2012:384017. doi:10.1155/2012/384017
Schultze SM, Jensen J, Hemmings BA, Tschopp O, Niessen M (2011) Promiscuous affairs of PKB/AKT isoforms in metabolism. Arch Physiol Biochem 117(2):70–77. doi:10.3109/13813455.2010.539236
Bayascas JR (2008) Dissecting the role of the 3-phosphoinositide-dependent protein kinase-1 (PDK1) signalling pathways. Cell Cycle 19:2978–2982
Maeda H, Rajesh KG, Maeda H, Suzuki R, Sasaguri S (2004) Epidermal growth factor and insulin inhibit cell death in pancreatic beta cells by activation of PI3-kinase/AKT signaling pathway under oxidative stress. Transplant Proc 36(4):1163–1165. doi:10.1016/j.transproceed.2004.04.018
Ohtsubo K, Chen MZ, Olefsky JM, Marth JD (2011) Pathway to diabetes through attenuation of pancreatic beta cell glycosylation and glucose transport. Nat Med 17(9):1067–1075. doi:10.1038/nm.2414
Bornfeldt KE, Tabas I (2011) Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab 14(5):575–585. doi:10.1016/j.cmet.2011.07.015
Henriksen EJ (2010) Dysregulation of glycogen synthase kinase-3 in skeletal muscle and the etiology of insulin resistance and type 2 diabetes. Curr Diabetes Rev 6(5):285–293
Saini V (2010) Molecular mechanisms of insulin resistance in type 2 diabetes mellitus. World J Diabetes 1(3):68–75. doi:10.4239/wjd.v1.i3.68
Szeman B, Nagy G, Varga T, Veres-Szekely A, Sasvari M, Fitala D, Szollosi A, Katonai R, Kotyuk E, Somogyi A (2012) Changes in cognitive function in patients with diabetes mellitus. Orv Hetil 153(9):323–329. doi:10.1556/OH.2012.29319
Freude S, Hettich MM, Schumann C, Stohr O, Koch L, Kohler C, Udelhoven M, Leeser U, Muller M, Kubota N, Kadowaki T, Krone W, Schroder H, Bruning JC, Schubert M (2009) Neuronal IGF-1 resistance reduces Abeta accumulation and protects against premature death in a model of Alzheimer's disease. FASEB J 23(10):3315–3324. doi:10.1096/fj.09-132043
Killick R, Scales G, Leroy K, Causevic M, Hooper C, Irvine EE, Choudhury AI, Drinkwater L, Kerr F, Al-Qassab H, Stephenson J, Yilmaz Z, Giese KP, Brion JP, Withers DJ, Lovestone S (2009) Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice. Biochem Biophys Res Commun 386(1):257–262. doi:10.1016/j.bbrc.2009.06.032
Dong X, Park S, Lin X, Copps K, Yi X, White MF (2006) Irs1 and Irs2 signaling is essential for hepatic glucose homeostasis and systemic growth. J Clin Investig 116(1):101–114. doi:10.1172/JCI25735
Shah OJ, Wang Z, Hunter T (2004) Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 14(18):1650–1656. doi:10.1016/j.cub.2004.08.026
Draznin B (2006) Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85alpha: the two sides of a coin. Diabetes 55(8):2392–2397. doi:10.2337/db06-0391
White MF (2002) IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 283(3):E413–E422. doi:10.1152/ajpendo.00514.2001
Samuel VT, Shulman GI (2012) Mechanisms for insulin resistance: common threads and missing links. Cell 148(5):852–871. doi:10.1016/j.cell.2012.02.017
Zhang H, Dellsperger KC, Zhang C (2012) The link between metabolic abnormalities and endothelial dysfunction in type 2 diabetes: an update. Basic Res Cardiol 107(1):237. doi:10.1007/s00395-011-0237-1
Dey D, Basu D, Roy SS, Bandyopadhyay A, Bhattacharya S (2006) Involvement of novel PKC isoforms in FFA induced defects in insulin signaling. Mol Cell Endocrinol 246(1–2):60–64. doi:10.1016/j.mce.2005.12.014
Timmers S, de Vogel-van den Bosch J, Hesselink MK, van Beurden D, Schaart G, Ferraz MJ, Losen M, Martinez-Martinez P, De Baets MH, Aerts JM, Schrauwen P (2011) Paradoxical increase in TAG and DAG content parallel the insulin sensitizing effect of unilateral DGAT1 overexpression in rat skeletal muscle. PLoS One 6(1):e14503. doi:10.1371/journal.pone.0014503
Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX (2009) Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease. J Neurochem 111(1):242–249. doi:10.1111/j.1471-4159.2009.06320.x
Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX (2011) Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. J Pathol 225(1):54–62. doi:10.1002/path.2912
Jolivalt CG, Lee CA, Beiswenger KK, Smith JL, Orlov M, Torrance MA, Masliah E (2008) Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin. J Neurosci Res 86(15):3265–3274. doi:10.1002/jnr.21787
Waite K, Eickholt BJ (2010) The neurodevelopmental implications of PI3K signaling. Curr Top Microbiol Immunol 346:245–265. doi:10.1007/82_2010_82
Peyrou M, Bourgoin L, Foti M (2010) PTEN in liver diseases and cancer. World J Gastroenterol 16(37):4627–4633
Rosivatz E, Matthews JG, McDonald NQ, Mulet X, Ho KK, Lossi N, Schmid AC, Mirabelli M, Pomeranz KM, Erneux C, Lam EW, Vilar R, Woscholski R (2006) A small molecule inhibitor for phosphatase and tensin homologue deleted on chromosome 10 (PTEN). ACS Chem Biol 1(12):780–790. doi:10.1021/cb600352f
Barbour LA, Shao J, Qiao L, Leitner W, Anderson M, Friedman JE, Draznin B (2004) Human placental growth hormone increases expression of the p85 regulatory unit of phosphatidylinositol 3-kinase and triggers severe insulin resistance in skeletal muscle. Endocrinology 145(3):1144–1150. doi:10.1210/en.2003-1297
Kirwan JP, Varastehpour A, Jing M, Presley L, Shao J, Friedman JE, Catalano PM (2004) Reversal of insulin resistance postpartum is linked to enhanced skeletal muscle insulin signaling. J Clin Endocrinol Metab 89(9):4678–4684. doi:10.1210/jc.2004-0749
Ueki K, Fruman DA, Brachmann SM, Tseng YH, Cantley LC, Kahn CR (2002) Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Mol Cell Biol 22(3):965–977
Liao Y, Hung MC (2010) Physiological regulation of Akt activity and stability. Am J Transl Res 2(1):19–42
Tan SX, Ng Y, Meoli CC, Kumar A, Khoo PS, Fazakerley DJ, Junutula JR, Vali S, James DE, Stockli J (2012) Amplification and demultiplexing in insulin-regulated Akt protein kinase pathway in adipocytes. J Biol Chem 287(9):6128–6138. doi:10.1074/jbc.M111.318238
George S, Rochford JJ, Wolfrum C, Gray SL, Schinner S, Wilson JC, Soos MA, Murgatroyd PR, Williams RM, Acerini CL, Dunger DB, Barford D, Umpleby AM, Wareham NJ, Davies HA, Schafer AJ, Stoffel M, O'Rahilly S, Barroso I (2004) A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science 304(5675):1325–1328. doi:10.1126/science.1096706
Xu N, Lao Y, Zhang Y, Gillespie DA (2012) Akt: a double-edged sword in cell proliferation and genome stability. J Oncol 2012:951724. doi:10.1155/2012/951724
Sakamaki J, Daitoku H, Ueno K, Hagiwara A, Yamagata K, Fukamizu A (2011) Arginine methylation of BCL-2 antagonist of cell death (BAD) counteracts its phosphorylation and inactivation by Akt. Proc Natl Acad Sci U S A 108(15):6085–6090. doi:10.1073/pnas.1015328108
Wolfrum C, Besser D, Luca E, Stoffel M (2003) Insulin regulates the activity of forkhead transcription factor Hnf-3beta/Foxa-2 by Akt-mediated phosphorylation and nuclear/cytosolic localization. Proc Natl Acad Sci U S A 100(20):11624–11629. doi:10.1073/pnas.1931483100
Zhao X, Gan L, Pan H, Kan D, Majeski M, Adam SA, Unterman TG (2004) Multiple elements regulate nuclear/cytoplasmic shuttling of FOXO1: characterization of phosphorylation- and 14-3-3-dependent and -independent mechanisms. Biochem J 378(Pt 3):839–849. doi:10.1042/BJ20031450
Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129(7):1261–1274. doi:10.1016/j.cell.2007.06.009
Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307(5712):1098–1101. doi:10.1126/science.1106148
Cheng Z, Tseng Y, White MF (2010) Insulin signaling meets mitochondria in metabolism. Trends Endocrinol Metab 21(10):589–598. doi:10.1016/j.tem.2010.06.005
Fraenkel M, Ketzinel-Gilad M, Ariav Y, Pappo O, Karaca M, Castel J, Berthault MF, Magnan C, Cerasi E, Kaiser N, Leibowitz G (2008) mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 57(4):945–957. doi:10.2337/db07-0922
2Le Bacquer O, Petroulakis E, Paglialunga S, Poulin F, Richard D, Cianflone K, Sonenberg N (2007) Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2. J Clin Invest 117(2):387–396. doi:10.1172/JCI29528
Ma XM, Blenis J (2009) Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10(5):307–318. doi:10.1038/nrm2672
Mariappan MM (2012) Signaling mechanisms in the regulation of renal matrix metabolism in diabetes. Exp Diabetes Res 2012:749812. doi:10.1155/2012/749812
Proud CG (2007) Signalling to translation: how signal transduction pathways control the protein synthetic machinery. Biochem J 403(2):217–234. doi:10.1042/BJ20070024
Kaidanovich-Beilin O, Woodgett JR (2011) GSK-3: functional Insights from Cell Biology and Animal Models. Front Mol Neurosci 4:40. doi:10.3389/fnmol.2011.00040
Medina M, Garrido JJ, Wandosell FG (2011) Modulation of GSK-3 as a therapeutic strategy on tau pathologies. Front Mol Neurosci 4:24. doi:10.3389/fnmol.2011.00024
Poljsak B (2011) Strategies for reducing or preventing the generation of oxidative stress. Oxidative Med Cell Longev 2011:194586. doi:10.1155/2011/194586
Schubert M, Brazil DP, Burks DJ, Kushner JA, Ye J, Flint CL, Farhang-Fallah J, Dikkes P, Warot XM, Rio C, Corfas G, White MF (2003) Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci 23(18):7084–7092
Maher PA, Schubert DR (2009) Metabolic links between diabetes and Alzheimer's disease. Expert Rev Neurother 9(5):617–630. doi:10.1586/ern.09.18
Besnard A, Galan-Rodriguez B, Vanhoutte P, Caboche J (2011) Elk-1 a transcription factor with multiple facets in the brain. Front Neurosci 5:35. doi:10.3389/fnins.2011.00035
Jeanneteau F, Deinhardt K (2011) Fine-tuning MAPK signaling in the brain: the role of MKP-1. Commun Integr Biol 4(3):281–283. doi:10.4161/cib.4.3.14766
Sharma SK, Carew TJ (2004) The roles of MAPK cascades in synaptic plasticity and memory in Aplysia: facilitatory effects and inhibitory constraints. Learn Mem 11(4):373–378. doi:10.1101/lm.81104
Kim SH, Smith CJ, Van Eldik LJ (2004) Importance of MAPK pathways for microglial pro-inflammatory cytokine IL-1 beta production. Neurobiol Aging 25(4):431–439. doi:10.1016/S0197-4580(03)00126-X
Hu JF, Niu F, Ning N, Duan WZ, Chu SF, Xue W, Yuan YH, Chen NH, Zhang JT (2012) Activation of ERK1/2-CREB pathway during potentiating synaptic transmission of (−)clausenamide in rat dentate gyrus. J Asian Nat Prod Res 14(3):256–262. doi:10.1080/10286020.2011.650885
Chico LK, Van Eldik LJ, Watterson DM (2009) Targeting protein kinases in central nervous system disorders. Nat Rev Drug Discov 8(11):892–909. doi:10.1038/nrd2999
Munoz L, Ammit AJ (2010) Targeting p38 MAPK pathway for the treatment of Alzheimer's disease. Neuropharmacology 58(3):561–568. doi:10.1016/j.neuropharm.2009.11.010
Kelleher I, Garwood C, Hanger DP, Anderton BH, Noble W (2007) Kinase activities increase during the development of tauopathy in htau mice. J Neurochem 103(6):2256–2267. doi:10.1111/j.1471-4159.2007.04930.x
Baker LD, Cross DJ, Minoshima S, Belongia D, Watson GS, Craft S (2011) Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol 68(1):51–57. doi:10.1001/archneurol.2010.225
Zhao WQ, Townsend M (2009) Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochim Biophys Acta 1792(5):482–496. doi:10.1016/j.bbadis.2008.10.014
Scheepers A, Joost HG, Schurmann A (2004) The glucose transporter families SGLT and GLUT: molecular basis of normal and aberrant function. J Parenter Enter Nutr 28(5):364–371
Schulingkamp RJ, Pagano TC, Hung D, Raffa RB (2000) Insulin receptors and insulin action in the brain: review and clinical implications. Neurosci Biobehav Rev 24(8):855–872
Gomez Ravetti M, Rosso OA, Berretta R, Moscato P (2010) Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease. PLoS One 5(4):e10153. doi:10.1371/journal.pone.0010153
Hooijmans CR, Graven C, Dederen PJ, Tanila H, van Groen T, Kiliaan AJ (2007) Amyloid beta deposition is related to decreased glucose transporter-1 levels and hippocampal atrophy in brains of aged APP/PS1 mice. Brain Res 1181:93–103. doi:10.1016/j.brainres.2007.08.063
Liu Y, Liu F, Iqbal K, Grundke-Iqbal I, Gong CX (2008) Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease. FEBS Lett 582(2):359–364. doi:10.1016/j.febslet.2007.12.035
Cavedo E, Frisoni GB (2011) The dynamic marker hypothesis of Alzheimer's disease and its implications for clinical imaging. Q J Nucl Med Mol Imaging 55(3):237–249
Garrido GE, Furuie SS, Buchpiguel CA, Bottino CM, Almeida OP, Cid CG, Camargo CH, Castro CC, Glabus MF, Busatto GF (2002) Relation between medial temporal atrophy and functional brain activity during memory processing in Alzheimer's disease: a combined MRI and SPECT study. J Neurol Neurosurg Psychiatry 73(5):508–516
Small GW, Ercoli LM, Silverman DH, Huang SC, Komo S, Bookheimer SY, Lavretsky H, Miller K, Siddarth P, Rasgon NL, Mazziotta JC, Saxena S, Wu HM, Mega MS, Cummings JL, Saunders AM, Pericak-Vance MA, Roses AD, Barrio JR, Phelps ME (2000) Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 97(11):6037–6042. doi:10.1073/pnas.090106797
Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J (2004) Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A 101(1):284–289. doi:10.1073/pnas.2635903100
Valla J, Gonzalez-Lima F, Reiman EM (2008) FDG autoradiography reveals developmental and pathological effects of mutant amyloid in PDAPP transgenic mice. Int J Dev Neurosci 26(3–4):253–258. doi:10.1016/j.ijdevneu.2008.02.003
Bubber P, Haroutunian V, Fisch G, Blass JP, Gibson GE (2005) Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann Neurol 57(5):695–703. doi:10.1002/ana.20474
Huang HM, Ou HC, Xu H, Chen HL, Fowler C, Gibson GE (2003) Inhibition of alpha-ketoglutarate dehydrogenase complex promotes cytochrome c release from mitochondria, caspase-3 activation, and necrotic cell death. J Neurosci Res 74(2):309–317. doi:10.1002/jnr.10756
Moreira PI, Santos MS, Oliveira CR (2007) Alzheimer's disease: a lesson from mitochondrial dysfunction. Antioxid Redox Signal 9(10):1621–1630. doi:10.1089/ars.2007.1703
Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414(6865):813–820. doi:10.1038/414813a
Yamagishi S (2011) Role of advanced glycation end products (AGEs) in osteoporosis in diabetes. Curr Drug Targets 12(14):2096–2102
Goh SY, Cooper ME (2008) Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 93(4):1143–1152. doi:10.1210/jc.2007-1817
Takuma K, Fang F, Zhang W, Yan S, Fukuzaki E, Du H, Sosunov A, McKhann G, Funatsu Y, Nakamichi N, Nagai T, Mizoguchi H, Ibi D, Hori O, Ogawa S, Stern DM, Yamada K, Yan SS (2009) RAGE-mediated signaling contributes to intraneuronal transport of amyloid-beta and neuronal dysfunction. Proc Natl Acad Sci U S A 106(47):20021–20026. doi:10.1073/pnas.0905686106
Biessels GJ, van der Heide LP, Kamal A, Bleys RL, Gispen WH (2002) Ageing and diabetes: implications for brain function. Eur J Pharmacol 441(1–2):1–14
Yan SD, Bierhaus A, Nawroth PP, Stern DM (2009) RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation? J Alzheimers Dis 16(4):833–843. doi:10.3233/JAD-2009-1030
Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM (1996) RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382(6593):685–691. doi:10.1038/382685a0
Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B (2003) RAGE mediates amyloid-beta peptide transport across the blood–brain barrier and accumulation in brain. Nat Med 9(7):907–913. doi:10.1038/nm890
Sato N, Takeda S, Uchio-Yamada K, Ueda H, Fujisawa T, Rakugi H, Morishita R (2011) Role of insulin signaling in the interaction between Alzheimer disease and diabetes mellitus: a missing link to therapeutic potential. Cur Aging Sci 4(2):118–127
Deane R, Singh I, Sagare AP, Bell RD, Ross NT, LaRue B, Love R, Perry S, Paquette N, Deane RJ, Thiyagarajan M, Zarcone T, Fritz G, Friedman AE, Miller BL, Zlokovic BV (2012) A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Investig 122(4):1377–1392. doi:10.1172/JCI58642
Xiong F, Leonov S, Howard AC, Xiong S, Zhang B, Mei L, McNeil P, Simon S, Xiong WC (2011) Receptor for advanced glycation end products (RAGE) prevents endothelial cell membrane resealing and regulates F-actin remodeling in a beta-catenin-dependent manner. J Biol Chem 286(40):35061–35070. doi:10.1074/jbc.M111.261073
Liu F, Iqbal K, Grundke-Iqbal I, Hart GW, Gong CX (2004) O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc Natl Acad Sci U S A 101(29):10804–10809. doi:10.1073/pnas.0400348101
Robertson LA, Moya KL, Breen KC (2004) The potential role of tau protein O-glycosylation in Alzheimer's disease. J Alzheimers Dis 6(5):489–495
Majumdar G, Wright J, Markowitz P, Martinez-Hernandez A, Raghow R, Solomon SS (2004) Insulin stimulates and diabetes inhibits O-linked N-acetylglucosamine transferase and O-glycosylation of Sp1. Diabetes 53(12):3184–3192
Liu F, Shi J, Tanimukai H, Gu J, Gu J, Grundke-Iqbal I, Iqbal K, Gong CX (2009) Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease. Brain 132(Pt 7):1820–1832. doi:10.1093/brain/awp099
Yuzwa SA, Shan X, Macauley MS, Clark T, Skorobogatko Y, Vosseller K, Vocadlo DJ (2012) Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. Nat Chem Biol 8(4):393–399. doi:10.1038/nchembio.797
Akter K, Lanza EA, Martin SA, Myronyuk N, Rua M, Raffa RB (2011) Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? Br J Clin Pharmacol 71(3):365–376. doi:10.1111/j.1365-2125.2010.03830.x
Ramasamy R, Yan SF, Schmidt AM (2011) Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann N Y Acad Sci 1243:88–102. doi:10.1111/j.1749-6632.2011.06320.x
Srikanth V, Maczurek A, Phan T, Steele M, Westcott B, Juskiw D, Munch G (2011) Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. Neurobiol Aging 32(5):763–777. doi:10.1016/j.neurobiolaging.2009.04.016
Kroner Z (2009) The relationship between Alzheimer's disease and diabetes: type 3 diabetes? Altern Med Rev 14(4):373–379
Di Paolo G, Kim TW (2011) Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat Rev Neurosci 12(5):284–296. doi:10.1038/nrn3012
Taskinen MR (2002) Diabetic dyslipidemia. Atheroscler Suppl 3(1):47–51
Roland I, De Leval X, Evrard B, Pirotte B, Dogne JM, Delattre L (2004) Modulation of the arachidonic cascade with omega3 fatty acids or analogues: potential therapeutic benefits. Mini Rev Med Chem 4(6):659–668
Eckel RH, Grundy SM, Zimmet PZ (2005) The metabolic syndrome. Lancet 365(9468):1415–1428. doi:10.1016/S0140-6736(05)66378-7
Hayashi H (2011) Lipid metabolism and glial lipoproteins in the central nervous system. Biol Pharm Bull 34(4):453–461
Jenkins AJ, Best JD, Klein RL, Lyons TJ (2004) Lipoproteins, glycoxidation and diabetic angiopathy. Diabetes Metabol Res Rev 20(5):349–368. doi:10.1002/dmrr.491
Lutjohann D (2006) Cholesterol metabolism in the brain: importance of 24S-hydroxylation. Acta Neurol Scand Suppl 185:33–42. doi:10.1111/j.1600-0404.2006.00683.x
Hamel FG, Upward JL, Bennett RG (2003) In vitro inhibition of insulin-degrading enzyme by long-chain fatty acids and their coenzyme A thioesters. Endocrinology 144(6):2404–2408
Hillered L, Chan PH (1988) Role of arachidonic acid and other free fatty acids in mitochondrial dysfunction in brain ischemia. J Neurosci Res 20(4):451–456. doi:10.1002/jnr.490200407
Firuzi O, Zhuo J, Chinnici CM, Wisniewski T, Pratico D (2008) 5-Lipoxygenase gene disruption reduces amyloid-beta pathology in a mouse model of Alzheimer's disease. FASEB J 22(4):1169–1178. doi:10.1096/fj.07-9131.com
Sanchez-Mejia RO, Newman JW, Toh S, Yu GQ, Zhou Y, Halabisky B, Cisse M, Scearce-Levie K, Cheng IH, Gan L, Palop JJ, Bonventre JV, Mucke L (2008) Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat Neurosci 11(11):1311–1318. doi:10.1038/nn.2213
Cherny VV, Henderson LM, Xu W, Thomas LL, DeCoursey TE (2001) Activation of NADPH oxidase-related proton and electron currents in human eosinophils by arachidonic acid. J Physiol 535(Pt 3):783–794
Zhu D, Lai Y, Shelat PB, Hu C, Sun GY, Lee JC (2006) Phospholipases A2 mediate amyloid-beta peptide-induced mitochondrial dysfunction. J Neurosci Off J Soc Neurosci 26(43):11111–11119. doi:10.1523/JNEUROSCI.3505-06.2006
Penzo D, Petronilli V, Angelin A, Cusan C, Colonna R, Scorrano L, Pagano F, Prato M, Di Lisa F, Bernardi P (2004) Arachidonic acid released by phospholipase A(2) activation triggers Ca(2+)-dependent apoptosis through the mitochondrial pathway. J Biol Chem 279(24):25219–25225. doi:10.1074/jbc.M310381200
Tan S, Sagara Y, Liu Y, Maher P, Schubert D (1998) The regulation of reactive oxygen species production during programmed cell death. J Cell Biol 141(6):1423–1432
Puccio S, Chu J, Pratico D (2011) Involvement of 5-lipoxygenase in the corticosteroid-dependent amyloid beta formation: in vitro and in vivo evidence. PLoS One 6(1):e15163. doi:10.1371/journal.pone.0015163
Claria J (2003) Cyclooxygenase-2 biology. Curr Pharm Des 9(27):2177–2190
Sun GY, Horrocks LA, Farooqui AA (2007) The roles of NADPH oxidase and phospholipases A2 in oxidative and inflammatory responses in neurodegenerative diseases. J Neurochem 103(1):1–16. doi:10.1111/j.1471-4159.2007.04670.x
Sims-Robinson C, Kim B, Rosko A, Feldman EL (2010) How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol 6(10):551–559. doi:10.1038/nrneurol.2010.130
Yaffe K (2007) Metabolic syndrome and cognitive decline. Curr Alzheimer Res 4(2):123–126
Dietschy JM, Turley SD (2001) Cholesterol metabolism in the brain. Curr Opin Lipidol 12(2):105–112
Bjorkhem I (2006) Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain. J Intern Med 260(6):493–508. doi:10.1111/j.1365-2796.2006.01725.x
Chang TY, Chang CC, Ohgami N, Yamauchi Y (2006) Cholesterol sensing, trafficking, and esterification. Annu Rev Cell Dev Biol 22:129–157. doi:10.1146/annurev.cellbio.22.010305.104656
Heverin M, Meaney S, Lutjohann D, Diczfalusy U, Wahren J, Bjorkhem I (2005) Crossing the barrier: net flux of 27-hydroxycholesterol into the human brain. J Lipid Res 46(5):1047–1052. doi:10.1194/jlr.M500024-JLR200
Ladu MJ, Reardon C, Van Eldik L, Fagan AM, Bu G, Holtzman D, Getz GS (2000) Lipoproteins in the central nervous system. Ann N Y Acad Sci 903:167–175
Bhattacharyya R, Kovacs DM (2010) ACAT inhibition and amyloid beta reduction. Biochim Biophys Acta 1801(8):960–965. doi:10.1016/j.bbalip.2010.04.003
Hutter-Paier B, Huttunen HJ, Puglielli L, Eckman CB, Kim DY, Hofmeister A, Moir RD, Domnitz SB, Frosch MP, Windisch M, Kovacs DM (2004) The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease. Neuron 44(2):227–238. doi:10.1016/j.neuron.2004.08.043
Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K (1998) Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A 95(11):6460–6464
Vetrivel KS, Thinakaran G (2010) Membrane rafts in Alzheimer's disease beta-amyloid production. Biochim Biophys Acta 1801(8):860–867. doi:10.1016/j.bbalip.2010.03.007
Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE (2008) ApoE promotes the proteolytic degradation of Abeta. Neuron 58(5):681–693. doi:10.1016/j.neuron.2008.04.010
Peila R, Rodriguez BL, Launer LJ, Honolulu-Asia Aging S (2002) Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu–Asia Aging Study. Diabetes 51(4):1256–1262
Belinson H, Lev D, Masliah E, Michaelson DM (2008) Activation of the amyloid cascade in apolipoprotein E4 transgenic mice induces lysosomal activation and neurodegeneration resulting in marked cognitive deficits. J Neurosci Off J Soc Neurosci 28(18):4690–4701. doi:10.1523/JNEUROSCI.5633-07.2008
Brecht WJ, Harris FM, Chang S, Tesseur I, Yu GQ, Xu Q, Dee Fish J, Wyss-Coray T, Buttini M, Mucke L, Mahley RW, Huang Y (2004) Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J Neurosci Off J Soc Neurosci 24(10):2527–2534. doi:10.1523/JNEUROSCI.4315-03.2004
Luchsinger JA (2012) Type 2 diabetes and cognitive impairment: linking mechanisms. J Alzheimers Dis 30:S185–S198. doi:10.3233/JAD-2012-111433
Chaudhary R, Likidlilid A, Peerapatdit T, Tresukosol D, Srisuma S, Ratanamaneechat S, Sriratanasathavorn C (2012) Apolipoprotein E gene polymorphism: effects on plasma lipids and risk of type 2 diabetes and coronary artery disease. Cardiovasc Diabetol 11:36. doi:10.1186/1475-2840-11-36
Hayden MR, Clee SM, Brooks-Wilson A, Genest J Jr, Attie A, Kastelein JJ (2000) Cholesterol efflux regulatory protein, Tangier disease and familial high-density lipoprotein deficiency. Curr Opin Lipidol 11(2):117–122
Koldamova R, Fitz NF, Lefterov I (2010) The role of ATP-binding cassette transporter A1 in Alzheimer's disease and neurodegeneration. Biochim Biophys Acta 1801(8):824–830. doi:10.1016/j.bbalip.2010.02.010
Hirsch-Reinshagen V, Zhou S, Burgess BL, Bernier L, McIsaac SA, Chan JY, Tansley GH, Cohn JS, Hayden MR, Wellington CL (2004) Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J Biol Chem 279(39):41197–41207. doi:10.1074/jbc.M407962200
Wang XT, Li J, Liu L, Hu N, Jin S, Liu C, Mei D, Liu XD (2012) Tissue cholesterol content alterations in streptozotocin-induced diabetic rats. Acta Pharmacol Sin 33(7):909–917. doi:10.1038/aps.2012.50
Lei P, Wu WH, Li RW, Ma JW, Yu YP, Cui W, Zhao YF, Li YM (2008) Prevention and promotion effects of apolipoprotein E4 on amylin aggregation. Biochem Biophys Res Commun 368(2):414–418. doi:10.1016/j.bbrc.2008.01.103
Mattson MP, Gleichmann M, Cheng A (2008) Mitochondria in neuroplasticity and neurological disorders. Neuron 60(5):748–766. doi:10.1016/j.neuron.2008.10.010
Moreira PI, Duarte AI, Santos MS, Rego AC, Oliveira CR (2009) An integrative view of the role of oxidative stress, mitochondria and insulin in Alzheimer's disease. J Alzheimers Dis 16(4):741–761. doi:10.3233/JAD-2009-0972
Chen H, Chan DC (2009) Mitochondrial dynamics—fusion, fission, movement, and mitophagy—in neurodegenerative diseases. Hum Mol Genet 18(R2):R169–R176. doi:10.1093/hmg/ddp326
Perez-Matute P, Zulet MA, Martinez JA (2009) Reactive species and diabetes: counteracting oxidative stress to improve health. Curr Opin Pharmacol 9(6):771–779. doi:10.1016/j.coph.2009.08.005
Jomova K, Valko M (2011) Advances in metal-induced oxidative stress and human disease. Toxicology 283(2–3):65–87. doi:10.1016/j.tox.2011.03.001
Malinouski M, Zhou Y, Belousov VV, Hatfield DL, Gladyshev VN (2011) Hydrogen peroxide probes directed to different cellular compartments. PLoS One 6(1):e14564. doi:10.1371/journal.pone.0014564
Jiang D, Li X, Williams R, Patel S, Men L, Wang Y, Zhou F (2009) Ternary complexes of iron, amyloid-beta, and nitrilotriacetic acid: binding affinities, redox properties, and relevance to iron-induced oxidative stress in Alzheimer's disease. Biochemistry 48(33):7939–7947. doi:10.1021/bi900907a
Lipinski B (2011) Hydroxyl radical and its scavengers in health and disease. Oxidative Med Cell Longev 2011:809696. doi:10.1155/2011/809696
Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J (2007) Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39(1):44–84. doi:10.1016/j.biocel.2006.07.001
Flora SJ (2007) Role of free radicals and antioxidants in health and disease. Cell Mol Biol 53(1):1–2
Bonda DJ, Wang X, Perry G, Nunomura A, Tabaton M, Zhu X, Smith MA (2010) Oxidative stress in Alzheimer disease: a possibility for prevention. Neuropharmacology 59(4–5):290–294. doi:10.1016/j.neuropharm.2010.04.005
Hampel H, Prvulovic D, Teipel S, Jessen F, Luckhaus C, Frolich L, Riepe MW, Dodel R, Leyhe T, Bertram L, Hoffmann W, Faltraco F, German Task Force on Alzheimer's D (2011) The future of Alzheimer's disease: the next 10 years. Prog Neurobiol 95(4):718–728. doi:10.1016/j.pneurobio.2011.11.008
Pratico D, Delanty N (2000) Oxidative injury in diseases of the central nervous system: focus on Alzheimer's disease. Am J Med 109(7):577–585
Obel LF, Muller MS, Walls AB, Sickmann HM, Bak LK, Waagepetersen HS, Schousboe A (2012) Brain glycogen-new perspectives on its metabolic function and regulation at the subcellular level. Front Neuroenerg 4:3. doi:10.3389/fnene.2012.00003
Readnower RD, Sauerbeck AD, Sullivan PG (2011) Mitochondria, amyloid beta, and Alzheimer's disease. Int J Alzheimers Dis 2011:104545. doi:10.4061/2011/104545
Sultana R, Butterfield DA (2011) Identification of the oxidative stress proteome in the brain. Free Radic Biol Med 50(4):487–494. doi:10.1016/j.freeradbiomed.2010.11.021
Ceriello A, Mercuri F, Quagliaro L, Assaloni R, Motz E, Tonutti L, Taboga C (2001) Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia 44(7):834–838. doi:10.1007/s001250100529
Douglas G, Bendall JK, Crabtree MJ, Tatham AL, Carter EE, Hale AB, Channon KM (2012) Endothelial-specific Nox2 overexpression increases vascular superoxide and macrophage recruitment in ApoE(−)/(−) mice. Cardiovasc Res 94(1):20–29. doi:10.1093/cvr/cvs026
Rolo AP, Palmeira CM (2006) Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol Appl Pharmacol 212(2):167–178. doi:10.1016/j.taap.2006.01.003
Zhu X, Perry G, Smith MA, Wang X (2012) Abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease. J Alzheimers Dis. doi:10.3233/JAD-2012-129005
Andreyev AY, Kushnareva YE, Starkov AA (2005) Mitochondrial metabolism of reactive oxygen species. Biochem Biokhim 70(2):200–214
Brand MD (2010) The sites and topology of mitochondrial superoxide production. Exp Gerontol 45(7–8):466–472. doi:10.1016/j.exger.2010.01.003
Murphy MP (2009) How mitochondria produce reactive oxygen species. Biochem J 417(1):1–13. doi:10.1042/BJ20081386
Selivanov VA, Votyakova TV, Pivtoraiko VN, Zeak J, Sukhomlin T, Trucco M, Roca J, Cascante M (2011) Reactive oxygen species production by forward and reverse electron fluxes in the mitochondrial respiratory chain. PLoS Comput Biol 7(3):e1001115. doi:10.1371/journal.pcbi.1001115
Ten VS, Starkov A (2012) Hypoxic–ischemic injury in the developing brain: the role of reactive oxygen species originating in mitochondria. Neurol Res Int 2012:542976. doi:10.1155/2012/542976
Spuch C, Ortolano S, Navarro C (2012) New insights in the amyloid-beta interaction with mitochondria. J Aging Res 2012:324968. doi:10.1155/2012/324968
Drechsel DA, Estevez AG, Barbeito L, Beckman JS (2012) Nitric oxide-mediated oxidative damage and the progressive demise of motor neurons in ALS. Neurotox Res. doi:10.1007/s12640-012-9322-y
Smith MA, Zhu X, Tabaton M, Liu G, McKeel DW Jr, Cohen ML, Wang X, Siedlak SL, Dwyer BE, Hayashi T, Nakamura M, Nunomura A, Perry G (2010) Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J Alzheimers Dis 19(1):363–372. doi:10.3233/JAD-2010-1239
Di Domenico F, Coccia R, Butterfield DA, Perluigi M (2011) Circulating biomarkers of protein oxidation for Alzheimer disease: expectations within limits. Biochim Biophys Acta 1814(12):1785–1795. doi:10.1016/j.bbapap.2011.10.001
Lim YA, Grimm A, Giese M, Mensah-Nyagan AG, Villafranca JE, Ittner LM, Eckert A, Gotz J (2011) Inhibition of the mitochondrial enzyme ABAD restores the amyloid-beta-mediated deregulation of estradiol. PLoS One 6(12):e28887. doi:10.1371/journal.pone.0028887
Lustbader JW, Cirilli M, Lin C, Xu HW, Takuma K, Wang N, Caspersen C, Chen X, Pollak S, Chaney M, Trinchese F, Liu S, Gunn-Moore F, Lue LF, Walker DG, Kuppusamy P, Zewier ZL, Arancio O, Stern D, Yan SS, Wu H (2004) ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 304(5669):448–452. doi:10.1126/science.1091230
Janciauskiene S, Ahren B (2000) Fibrillar islet amyloid polypeptide differentially affects oxidative mechanisms and lipoprotein uptake in correlation with cytotoxicity in two insulin-producing cell lines. Biochem Biophys Res Commun 267(2):619–625. doi:10.1006/bbrc.1999.1989
Konarkowska B, Aitken JF, Kistler J, Zhang S, Cooper GJ (2005) Thiol reducing compounds prevent human amylin-evoked cytotoxicity. FEBS J 272(19):4949–4959. doi:10.1111/j.1742-4658.2005.04903.x
Folli F, Guzzi V, Perego L, Coletta DK, Finzi G, Placidi C, La Rosa S, Capella C, Socci C, Lauro D, Tripathy D, Jenkinson C, Paroni R, Orsenigo E, Cighetti G, Gregorini L, Staudacher C, Secchi A, Bachi A, Brownlee M, Fiorina P (2010) Proteomics reveals novel oxidative and glycolytic mechanisms in type 1 diabetic patients' skin which are normalized by kidney–pancreas transplantation. PLoS One 5(3):e9923. doi:10.1371/journal.pone.0009923
Gersten RA, Gretebeck LM, Hildick-Smith G, Sandwick RK (2010) Maillard reaction of ribose 5-phosphate generates superoxide and glycation products for bovine heart cytochrome c reduction. Carbohydr Res 345(17):2499–2506. doi:10.1016/j.carres.2010.09.013
Kassab A, Piwowar A (2012) Cell oxidant stress delivery and cell dysfunction onset in type 2 diabetes. Biochimie 94(9):1837–1848. doi:10.1016/j.biochi.2012.01.020
Munusamy S, MacMillan-Crow LA (2009) Mitochondrial superoxide plays a crucial role in the development of mitochondrial dysfunction during high glucose exposure in rat renal proximal tubular cells. Free Radic Biol Med 46(8):1149–1157. doi:10.1016/j.freeradbiomed.2009.01.022
Pacher P, Szabo C (2005) Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme. Antioxid Redox Signal 7(11–12):1568–1580. doi:10.1089/ars.2005.7.1568
Perry SW, Norman JP, Barbieri J, Brown EB, Gelbard HA (2011) Mitochondrial membrane potential probes and the proton gradient: a practical usage guide. Biotechniques 50(2):98–115. doi:10.2144/000113610
Vincent AM, Olzmann JA, Brownlee M, Sivitz WI, Russell JW (2004) Uncoupling proteins prevent glucose-induced neuronal oxidative stress and programmed cell death. Diabetes 53(3):726–734
Mastrocola R, Restivo F, Vercellinatto I, Danni O, Brignardello E, Aragno M, Boccuzzi G (2005) Oxidative and nitrosative stress in brain mitochondria of diabetic rats. J Endocrinol 187(1):37–44. doi:10.1677/joe.1.06269
Cardoso S, Carvalho C, Santos R, Correia S, Santos MS, Seica R, Oliveira CR, Moreira PI (2011) Impact of STZ-induced hyperglycemia and insulin-induced hypoglycemia in plasma amino acids and cortical synaptosomal neurotransmitters. Synapse 65(6):457–466. doi:10.1002/syn.20863
Raza H, Prabu SK, John A, Avadhani NG (2011) Impaired mitochondrial respiratory functions and oxidative stress in streptozotocin-induced diabetic rats. Int J Mol Sci 12(5):3133–3147. doi:10.3390/ijms12053133
Giacco F, Brownlee M (2010) Oxidative stress and diabetic complications. Circ Res 107(9):1058–1070. doi:10.1161/CIRCRESAHA.110.223545
Rahmadi A, Steiner N, Munch G (2011) Advanced glycation endproducts as gerontotoxins and biomarkers for carbonyl-based degenerative processes in Alzheimer's disease. Clin Chem Lab Med 49(3):385–391. doi:10.1515/CCLM.2011.079
Thomas MC (2011) Advanced glycation end products. Contrib Nephrol 170:66–74. doi:10.1159/000324945
Higaki Y, Mikami T, Fujii N, Hirshman MF, Koyama K, Seino T, Tanaka K, Goodyear LJ (2008) Oxidative stress stimulates skeletal muscle glucose uptake through a phosphatidylinositol 3-kinase-dependent pathway. Am J Physiol Endocrinol Metab 294(5):E889–E897. doi:10.1152/ajpendo.00150.2007
Pitocco D, Zaccardi F, Di Stasio E, Romitelli F, Santini SA, Zuppi C, Ghirlanda G (2010) Oxidative stress, nitric oxide, and diabetes. Rev Diabet Stud 7(1):15–25. doi:10.1900/RDS.2010.7.15
Pessler D, Rudich A, Bashan N (2001) Oxidative stress impairs nuclear proteins binding to the insulin responsive element in the GLUT4 promoter. Diabetologia 44(12):2156–2164. doi:10.1007/s001250100024
Powell DJ, Hajduch E, Kular G, Hundal HS (2003) Ceramide disables 3-phosphoinositide binding to the pleckstrin homology domain of protein kinase B (PKB)/Akt by a PKCzeta-dependent mechanism. Mol Cell Biol 23(21):7794–7808
Corsinovi L, Biasi F, Poli G, Leonarduzzi G, Isaia G (2011) Dietary lipids and their oxidized products in Alzheimer's disease. Mol Nutr Food Res 55(Suppl 2):S161–S172. doi:10.1002/mnfr.201100208
Yang H, Jin X, Kei Lam CW, Yan SK (2011) Oxidative stress and diabetes mellitus. Clin Chem Lab Med CCLM/FESCC 49(11):1773–1782. doi:10.1515/CCLM.2011.250
Butterfield DA, Perluigi M, Reed T, Muharib T, Hughes CP, Robinson RA, Sultana R (2012) Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications. Antioxid Redox Signal. doi:10.1089/ars.2011.4109
Otaegui-Arrazola A, Menendez-Carreno M, Ansorena D, Astiasaran I (2010) Oxysterols: a world to explore. Food Chem Toxicol Int J Publ Br Ind Biol Res Assoc 48(12):3289–3303. doi:10.1016/j.fct.2010.09.023
Sottero B, Gamba P, Gargiulo S, Leonarduzzi G, Poli G (2009) Cholesterol oxidation products and disease: an emerging topic of interest in medicinal chemistry. Curr Med Chem 16(6):685–705
Famer D, Meaney S, Mousavi M, Nordberg A, Bjorkhem I, Crisby M (2007) Regulation of alpha- and beta-secretase activity by oxysterols: cerebrosterol stimulates processing of APP via the alpha-secretase pathway. Biochem Biophys Res Commun 359(1):46–50. doi:10.1016/j.bbrc.2007.05.033
Chen CT, Green JT, Orr SK, Bazinet RP (2008) Regulation of brain polyunsaturated fatty acid uptake and turnover. Prostaglandins Leukot Essent Fat Acids 79(3–5):85–91. doi:10.1016/j.plefa.2008.09.003
Florent-Bechard S, Desbene C, Garcia P, Allouche A, Youssef I, Escanye MC, Koziel V, Hanse M, Malaplate-Armand C, Stenger C, Kriem B, Yen-Potin FT, Olivier JL, Pillot T, Oster T (2009) The essential role of lipids in Alzheimer's disease. Biochimie 91(6):804–809. doi:10.1016/j.biochi.2009.03.004
Schneider C, Porter NA, Brash AR (2008) Routes to 4-hydroxynonenal: fundamental issues in the mechanisms of lipid peroxidation. J Biol Chem 283(23):15539–15543. doi:10.1074/jbc.R800001200
Spickett CM, Wiswedel I, Siems W, Zarkovic K, Zarkovic N (2010) Advances in methods for the determination of biologically relevant lipid peroxidation products. Free Radic Res 44(10):1172–1202. doi:10.3109/10715762.2010.498476
Markesbery WR, Kryscio RJ, Lovell MA, Morrow JD (2005) Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann Neurol 58(5):730–735. doi:10.1002/ana.20629
Mufson EJ, Leurgans S (2010) Inability of plasma and urine F2A-isoprostane levels to differentiate mild cognitive impairment from Alzheimer's disease. Neurodegener Dis 7(1–3):139–142. doi:10.1159/000289224
Greilberger J, Fuchs D, Leblhuber F, Greilberger M, Wintersteiger R, Tafeit E (2010) Carbonyl proteins as a clinical marker in Alzheimer's disease and its relation to tryptophan degradation and immune activation. Clin Lab 56(9–10):441–448
Sun L, Shen W, Liu Z, Guan S, Liu J, Ding S (2010) Endurance exercise causes mitochondrial and oxidative stress in rat liver: effects of a combination of mitochondrial targeting nutrients. Life Sci 86(1–2):39–44. doi:10.1016/j.lfs.2009.11.003
Bradley MA, Markesbery WR, Lovell MA (2010) Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease. Free Radic Biol Med 48(12):1570–1576. doi:10.1016/j.freeradbiomed.2010.02.016
Dang TN, Arseneault M, Murthy V, Ramassamy C (2010) Potential role of acrolein in neurodegeneration and in Alzheimer's disease. Curr Mol Pharmacol 3(2):66–78
Singh M, Dang TN, Arseneault M, Ramassamy C (2010) Role of by-products of lipid oxidation in Alzheimer's disease brain: a focus on acrolein. J Alzheimers Dis 21(3):741–756. doi:10.3233/JAD-2010-100405
Bacot S, Bernoud-Hubac N, Baddas N, Chantegrel B, Deshayes C, Doutheau A, Lagarde M, Guichardant M (2003) Covalent binding of hydroxy-alkenals 4-HDDE, 4-HHE, and 4-HNE to ethanolamine phospholipid subclasses. J Lipid Res 44(5):917–926. doi:10.1194/jlr.M200450-JLR200
Butterfield DA, Bader Lange ML, Sultana R (2010) Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease. Biochim Biophys Acta 1801(8):924–929. doi:10.1016/j.bbalip.2010.02.005
Siegel SJ, Bieschke J, Powers ET, Kelly JW (2007) The oxidative stress metabolite 4-hydroxynonenal promotes Alzheimer protofibril formation. Biochemistry 46(6):1503–1510. doi:10.1021/bi061853s
Trachootham D, Lu W, Ogasawara MA, Nilsa RD, Huang P (2008) Redox regulation of cell survival. Antioxid Redox Signal 10(8):1343–1374. doi:10.1089/ars.2007.1957
Stadtman ER, Berlett BS (1998) Reactive oxygen-mediated protein oxidation in aging and disease. Drug Metab Rev 30(2):225–243. doi:10.3109/03602539808996310
Widmer R, Ziaja I, Grune T (2006) Protein oxidation and degradation during aging: role in skin aging and neurodegeneration. Free Radic Res 40(12):1259–1268. doi:10.1080/10715760600911154
Schopfer FJ, Baker PR, Freeman BA (2003) NO-dependent protein nitration: a cell signaling event or an oxidative inflammatory response? Trends Biochem Sci 28(12):646–654. doi:10.1016/j.tibs.2003.10.006
Sultana R, Poon HF, Cai J, Pierce WM, Merchant M, Klein JB, Markesbery WR, Butterfield DA (2006) Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol Dis 22(1):76–87. doi:10.1016/j.nbd.2005.10.004
Dalle-Donne I, Rossi R, Giustarini D, Colombo R, Milzani A (2007) S-glutathionylation in protein redox regulation. Free Radic Biol Med 43(6):883–898. doi:10.1016/j.freeradbiomed.2007.06.014
Giustarini D, Rossi R, Milzani A, Colombo R, Dalle-Donne I (2004) S-Glutathionylation: from redox regulation of protein functions to human diseases. J Cell Mol Med 8(2):201–212
Komosinska-Vassev K, Olczyk P, Winsz-Szczotka K, Kuznik-Trocha K, Klimek K, Olczyk K (2011) Age- and gender-related alteration in plasma advanced oxidation protein products (AOPP) and glycosaminoglycan (GAG) concentrations in physiological ageing. Clin Chem Lab Med, doi:10.1515/CCLM.2011.789
Kovacic P, Somanathan R (2011) Cell signaling and receptors in toxicity of advanced glycation end products (AGEs): alpha-dicarbonyls, radicals, oxidative stress and antioxidants. J Recept Signal Transduct Res 31(5):332–339. doi:10.3109/10799893.2011.607171
Kalousova M, Skrha J, Zima T (2002) Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res Acad Sci Bohemoslovaca 51(6):597–604
Aldred S, Bennett S, Mecocci P (2010) Increased low-density lipoprotein oxidation, but not total plasma protein oxidation, in Alzheimer's disease. Clin Biochem 43(3):267–271. doi:10.1016/j.clinbiochem.2009.08.021
Wehr H, Bednarska-Makaruk M, Graban A, Lipczynska-Lojkowska W, Rodo M, Bochynska A, Ryglewicz D (2009) Paraoxonase activity and dementia. J Neurol Sci 283(1–2):107–108. doi:10.1016/j.jns.2009.02.317
Malinski T (2007) Nitric oxide and nitroxidative stress in Alzheimer's disease. J Alzheimers Dis 11(2):207–218
Moreira PI, Nunomura A, Nakamura M, Takeda A, Shenk JC, Aliev G, Smith MA, Perry G (2008) Nucleic acid oxidation in Alzheimer disease. Free Radic Biol Med 44(8):1493–1505. doi:10.1016/j.freeradbiomed.2008.01.002
Wang J, Markesbery WR, Lovell MA (2006) Increased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment. J Neurochem 96(3):825–832. doi:10.1111/j.1471-4159.2005.03615.x
Lovell MA, Markesbery WR (2008) Oxidatively modified RNA in mild cognitive impairment. Neurobiol Dis 29(2):169–175. doi:10.1016/j.nbd.2007.07.030
Morocz M, Kalman J, Juhasz A, Sinko I, McGlynn AP, Downes CS, Janka Z, Rasko I (2002) Elevated levels of oxidative DNA damage in lymphocytes from patients with Alzheimer's disease. Neurobiol Aging 23(1):47–53
Lovell MA, Markesbery WR (2007) Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease. Nucleic Acids Res 35(22):7497–7504. doi:10.1093/nar/gkm821
Nunomura A, Hofer T, Moreira PI, Castellani RJ, Smith MA, Perry G (2009) RNA oxidation in Alzheimer disease and related neurodegenerative disorders. Acta Neuropathol 118(1):151–166. doi:10.1007/s00401-009-0508-1
Tal TL, Tanguay RL (2012) Non-coding RNAs—novel targets in neurotoxicity. Neurotoxicology 33(3):530–544. doi:10.1016/j.neuro.2012.02.013
Golbidi S, Ebadi SA, Laher I (2011) Antioxidants in the treatment of diabetes. Curr Diabetes Rev 7(2):106–125
Johansen JS, Harris AK, Rychly DJ, Ergul A (2005) Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc Diabetol 4(1):5. doi:10.1186/1475-2840-4-5
Vina J, Lloret A, Giraldo E, Badia MC, Alonso MD (2011) Antioxidant pathways in Alzheimer's disease: possibilities of intervention. Curr Pharm Des 17(35):3861–3864
Chakroborty S, Stutzmann GE (2011) Early calcium dysregulation in Alzheimer's disease: setting the stage for synaptic dysfunction. Sci China Life Sci 54(8):752–762. doi:10.1007/s11427-011-4205-7
Jeitner TM, Pinto JT, Krasnikov BF, Horswill M, Cooper AJ (2009) Transglutaminases and neurodegeneration. J Neurochem 109(Suppl 1):160–166. doi:10.1111/j.1471-4159.2009.05843.x
Kim S, Rhim H (2011) Effects of amyloid-beta peptides on voltage-gated L-type Ca(V)1.2 and Ca(V)1.3 Ca(2+) channels. Mol Cells 32(3):289–294. doi:10.1007/s10059-011-0075-x
Wiederkehr A, Wollheim CB (2008) Impact of mitochondrial calcium on the coupling of metabolism to insulin secretion in the pancreatic beta-cell. Cell Calcium 44(1):64–76. doi:10.1016/j.ceca.2007.11.004
Fernyhough P, Calcutt NA (2010) Abnormal calcium homeostasis in peripheral neuropathies. Cell Calcium 47(2):130–139. doi:10.1016/j.ceca.2009.11.008
Verkhratsky A, Fernyhough P (2008) Mitochondrial malfunction and Ca2+ dyshomeostasis drive neuronal pathology in diabetes. Cell Calcium 44(1):112–122. doi:10.1016/j.ceca.2007.11.010
Strum JC, Shehee R, Virley D, Richardson J, Mattie M, Selley P, Ghosh S, Nock C, Saunders A, Roses A (2007) Rosiglitazone induces mitochondrial biogenesis in mouse brain. J Alzheimers Dis 11(1):45–51
Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T (2011) Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 32(9):1626–1633. doi:10.1016/j.neurobiolaging.2009.10.009
Chesik D, De Keyser J, Wilczak N (2008) Insulin-like growth factor system regulates oligodendroglial cell behavior: therapeutic potential in CNS. J Mol Neurosci 35(1):81–90. doi:10.1007/s12031-008-9041-2
Chen LM, Lin ZY, Zhu YG, Lin N, Zhang J, Pan XD, Chen XC (2012) Ginsenoside Rg1 attenuates beta-amyloid generation via suppressing PPARgamma-regulated BACE1 activity in N2a-APP695 cells. Eur J Pharmacol 675(1–3):15–21. doi:10.1016/j.ejphar.2011.11.039
Nicolakakis N, Hamel E (2011) Neurovascular function in Alzheimer's disease patients and experimental models. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab 31(6):1354–1370. doi:10.1038/jcbfm.2011.43
Sodhi RK, Singh N, Jaggi AS (2011) Neuroprotective mechanisms of peroxisome proliferator-activated receptor agonists in Alzheimer's disease. Naunyn Schmiedeberg's Arch Pharmacol 384(2):115–124. doi:10.1007/s00210-011-0654-6
Hanyu H, Sato T, Kiuchi A, Sakurai H, Iwamoto T (2009) Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus. J Am Geriatr Soc 57(1):177–179. doi:10.1111/j.1532-5415.2009.02067.x
Zhao Q, Matsumoto K, Tsuneyama K, Tanaka K, Li F, Shibahara N, Miyata T, Yokozawa T (2011) Diabetes-induced central cholinergic neuronal loss and cognitive deficit are attenuated by tacrine and a Chinese herbal prescription, kangen-karyu: elucidation in type 2 diabetes db/db mice. J Pharmacol Sci 117(4):230–242
Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, Brunden KR, Wilson DA, Landreth GE (2012) ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 335(6075):1503–1506. doi:10.1126/science.1217697
Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK, Evans RM, Tontonoz P (2001) A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7(1):161–171
Lefebvre P, Benomar Y, Staels B (2010) Retinoid X receptors: common heterodimerization partners with distinct functions. Trends Endocrinol Metab 21(11):676–683. doi:10.1016/j.tem.2010.06.009
Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W (2006) From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 45(2):120–159. doi:10.1016/j.plipres.2005.12.002
Chen Y, Zhou K, Wang R, Liu Y, Kwak YD, Ma T, Thompson RC, Zhao Y, Smith L, Gasparini L, Luo Z, Xu H, Liao FF (2009) Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad Sci U S A 106(10):3907–3912. doi:10.1073/pnas.0807991106
Kickstein E, Krauss S, Thornhill P, Rutschow D, Zeller R, Sharkey J, Williamson R, Fuchs M, Kohler A, Glossmann H, Schneider R, Sutherland C, Schweiger S (2010) Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc Natl Acad Sci U S A 107(50):21830–21835. doi:10.1073/pnas.0912793107
Gupta A, Bisht B, Dey CS (2011) Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. Neuropharmacology 60(6):910–920. doi:10.1016/j.neuropharm.2011.01.033
Markaki M, Tavernarakis N (2010) Modeling human diseases in Caenorhabditis elegans. Biotechnol J 5(12):1261–1276. doi:10.1002/biot.201000183
Morcos M, Hutter H (2009) The model Caenorhabditis elegans in diabetes mellitus and Alzheimer's disease. J Alzheimers Dis 16(4):897–908. doi:10.3233/JAD-2009-0977
Wu Z, Smith JV, Paramasivam V, Butko P, Khan I, Cypser JR, Luo Y (2002) Ginkgo biloba extract EGb 761 increases stress resistance and extends life span of Caenorhabditis elegans. Cell Mol Biol 48(6):725–731
Dostal V, Link CD (2010) Assaying beta-amyloid toxicity using a transgenic C. elegans model. Journal of visualized experiments : JoVE (44). doi:10.3791/2252
Onken B, Driscoll M (2010) Metformin induces a dietary restriction-like state and the oxidative stress response to extend C. elegans Healthspan via AMPK, LKB1, and SKN-1. PLoS One 5(1):e8758. doi:10.1371/journal.pone.0008758
Saharia K, Arya U, Kumar R, Sahu R, Das CK, Gupta K, Dwivedi H, Subramaniam JR (2012) Reserpine modulates neurotransmitter release to extend lifespan and alleviate age-dependent Abeta proteotoxicity in Caenorhabditis elegans. Exp Gerontol 47(2):188–197. doi:10.1016/j.exger.2011.12.006
Acknowledgements
I highly acknowledge Dr. Paul R Ebert (Associate Professor, School of Biological Sciences, University of Queensland, Australia), Mr. Andrew Johnston (School of Biological Sciences, The University of Queensland, Australia) and Sultan Asad (Centre of Excellence in Molecular Biology, Lahore, Pakistan) for innovating suggestions and proof reading.
Conflict of interests
The author declares that he has no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ahmad, W. Overlapped Metabolic and Therapeutic Links between Alzheimer and Diabetes. Mol Neurobiol 47, 399–424 (2013). https://doi.org/10.1007/s12035-012-8352-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12035-012-8352-z